Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection
Status:
Terminated
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
This phase I clinical trial is studying the side effects and the best dose of vorinostat when
given together with paclitaxel and carboplatin in treating patients with metastatic or
recurrent solid tumors and human immunodeficiency virus (HIV) infection. Vorinostat may stop
the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used
in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the
growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving
vorinostat together with paclitaxel and carboplatin may kill more tumor cells.
NOTE: An administrative decision was made by NCI to halt further study of vorinostat in this
specific patient population as of February 1, 2013. No patients remain on vorinostat. Going
forward this study will determine the safety and tolerability of the paclitaxel and
carboplatin combination in this patient population.
Phase:
Phase 1
Details
Lead Sponsor:
AIDS Malignancy Consortium
Collaborators:
National Cancer Institute (NCI) The Emmes Company, LLC The EMMES Corporation University of Arkansas